ClinicalTrials.gg
CompletedNCT02735915Updated Apr 12, 2024Results posted

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 7 sites in 3 countries. Open to participants aged 68 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
68 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
37th of 46
70 · median 239
Started
2016
with 2 others
Phase 3
22 of 46
2 open now
Registered
19th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 37th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 19th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 68 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course. This study will also assess immune responses after re-vaccination with 2 additional doses of the HZ/su administered at ten years after first dose of initial vaccination course from study Zoster-003 (NCT00434577).

Read the detailed description

In this LTFU study (ZOSTER-060), subjects who received 2 doses of HZ/su in the earlier Zoster-003 (NCT00434577) study will be followed up at Month 108/Year 9 and Month 120/Year 10 post first dose of vaccine for safety and immunogenicity (humoral and cellular). In order to assess the effect of re-vaccination with 2 additional doses of HZ/su vaccine, all the subjects will receive 2 additional doses of the HZ/su vaccine, on a 0, 2-month schedule at ten years after the initial vaccination course in study Zoster-003 (NCT00434577), and will be followed for reactogenicity, safety and humoral and cellular immunogenicity (including persistence).

In alignment with the previous persistence timepoints, this study has no control group.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Immunogenicity
  • Safety
  • Long term follow-up
  • Adults
  • Herpes zoster
04

Who can participate

Ages eligible
68 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, ability to have scheduled contacts to allow evaluation during the study). Or subjects with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, vaccination visits, availability for follow-up contacts).
  • Written obtained from the subject prior to performance of any study specific procedure.
  • Previous participation in study ZOSTER-003 (NCT00434577), in group 50 µg gE / AS01B, and who completed the vaccination course (2 doses of HZ/su) in study ZOSTER-003 (NCT00434577).
  • Subjects are expected to enter the study (or complete Visit 1) as of the time they turn 108 months after first vaccination of previous vaccination course with HZ/su and not later than 111 months.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the first study visit (Day -29 to Day 0), or planned use during the study period.
  • Use or anticipated use of or immune-modifying drugs during the period starting six months prior to study start and during the whole study period. This includes chronic administration of (>14 consecutive days of prednisone at a dose of ≥20 mg/day [or equivalent]), long-acting immune-modifying agents (e.g., infliximab) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , [HIV] infection).
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine* within 8 days prior to or within 14 days after either dose of study vaccine.

E.g., inactivated and subunit vaccines, including inactivated and subunit influenza vaccines and pneumococcal conjugate vaccines.

  • Previous vaccination against HZ since initial vaccination in Zoster-003.
  • Administration of immunoglobulins and/or any blood products during the period starting 3 months before the study start, or planned administration during the study period.
  • History of previous HZ.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    GSK1437173A vaccine Group

    Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study

    Biological: Herpes Zoster Vaccine GSK1437173A

Interventions

06

What researchers measure

Primary outcomes

  1. Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations

    Anti-glycoprotein E (gE) Ab concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micro international units per milliliter (mIU/mL).

    Time frame: At Month 108 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

  2. Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations

    Anti-gE Ab concentrations were determined by ELISA, presented as GMCs and expressed in mIU/mL.

    Time frame: At Month 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

  3. Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.

    gE specific CD4 (2+) T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L, were determined by means of Intracellular Cytokine Staining (ICS) and expressed in T-cells/million cells.

    Time frame: At Month 108 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

  4. Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.

    gE specific CD4 (2+)T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L were determined by means of ICS and expressed in T-cells/million cells.

    Time frame: At Month 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

Secondary outcomes

  1. Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations by Each Age Category

    Anti-gE Ab concentrations as determined by ELISA by each age category (60-69 years of age \[YOA\] and ≥70 YOA at the time of initial vaccination).Antibody concentrations were presented as GMCs and expressed in mIU/mL.

    Time frame: At Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

  2. Frequencies of Antigen-specific CD4 (2+) T-cells by Each Age Category

    Antigen specific CD4 (2+) T-cells as determined by means of ICS and expressed in T-cells/million cells, by each age category (60-69 YOA and ≥ 70 YOA at the time of initial vaccination).

    Time frame: At Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

  3. Number of Subjects With Any Serious Adverse Events (SAEs) Related to Study Participation or to a Concurrent GSK Medication/Vaccine (Including GSK1437173A Administered During the Zoster-003 [NCT00434577] Study).

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Between Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).

  4. Anti-gE Specific Antibody (Ab) Concentrations

    Anti-gE antibody concentrations were determined by ELISA in all subjects, presented as GMCs and expressed in mIU/mL.

    Time frame: At 1 month post each re-vaccination dose (i.e. Month 121 and Month 123) and at 1 year post last re-vaccination dose (i.e., Month 134).

  5. Frequencies of Antigen-specific CD4 (2+) T-cells, Post Re-vaccination Course.

    Antigen specific CD4 (2+)T cells were determined by means of ICS and expressed in T-cells/million cells.

    Time frame: At 1 month post each re-vaccination dose (i.e. Month 121 and Month 123) and at 1 year post last re-vaccination dose (i.e., Month 134).

  6. Number of Subjects With Any and Grade 3 Solicited Local Symptoms.

    Assessed solicited local symptoms included: pain, redness and swelling at injection site. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, prevented normal every day activities. Grade 3 redness/swelling = symptoms spreading beyond a surface of (\>) 100 millimeters (mm).

    Time frame: Within 7 days (Days 0-6) after each vaccination and across doses, in the current study.

  7. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.

    Assessed solicited general symptoms included: fatigue, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and temperature \[higher than or equal to (≥) 37.5 degrees Celsius (°C) for axillary, oral or tympanic route\] and ≥38.0°C for rectal route. Grade 3 fatigue, gastrointestinal symptoms, headache, myalgia, shivering = symptoms that prevented normal activity. Grade 3 temperature = defined as fever higher than (\>) 39.0°C, regardless of the route used.

    Time frame: Within 7 days (Days 0-6) after each vaccination and across doses, in the current study.

  8. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) According to the Medical Dictionary for Regulatory Activities (MedDRA) Classification in All Subjects.

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within 30 days (Days 0-29) after each vaccination in the current study.

  9. Number of Subjects With Any, Related and Fatal SAEs.

    SAEs assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

    Time frame: From Dose 1 of re-vaccination (Month 120) until study end (Month 134).

  10. Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs).

    pIMDs assessed includes AEs that were autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related pIMDs= pIMDs assessed by the investigator as related to the vaccination.

    Time frame: From Dose 1 of re-vaccination (Month 120) until study end (Month 134).

07

Results

Posted Nov 1, 2019

Participant flow

Subjects who participated in the parent study Zoster-003 (NCT00434577),in GSK1437173A _MD Group and received a complete vaccination course(2 doses of 50 µg GSK1437173A) were offered participation in this Long Term Follow-Up study. A total of 70 subjects met the eligibility criteria \& consented to participate in Germany, Sweden and Czech Republic

Participant flow — Overall Study
MilestoneGSK1437173A Vaccine Group
Started70
Vaccinated62
Completed59
Not completed11
Withdrew: Not vaccinated but subject id assigned8
Withdrew: Withdrawal following sae2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryAnti-glycoprotein (gE) Specific Antibody (Ab) Concentrations

Anti-glycoprotein E (gE) Ab concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micro international units per milliliter (mIU/mL).

Time frame:
At Month 108 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Geometric mean · mIU/mL
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations
mIU/mLGSK1437173A Vaccine Group
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations9122.9 (7775.2 to 10704.1)
PrimaryAnti-glycoprotein (gE) Specific Antibody (Ab) Concentrations

Anti-gE Ab concentrations were determined by ELISA, presented as GMCs and expressed in mIU/mL.

Time frame:
At Month 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Geometric mean · mIU/mL
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations
mIU/mLGSK1437173A Vaccine Group
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations7384.0 (6202.8 to 8790.1)
PrimaryFrequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.

gE specific CD4 (2+) T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L, were determined by means of Intracellular Cytokine Staining (ICS) and expressed in T-cells/million cells.

Time frame:
At Month 108 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Median · CD4 T-cells/million cells
Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.
CD4 T-cells/million cellsGSK1437173A Vaccine Group
Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.414.0 (220.9 to 796.5)
PrimaryFrequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.

gE specific CD4 (2+)T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L were determined by means of ICS and expressed in T-cells/million cells.

Time frame:
At Month 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Median · CD4 T-cells/million cells
Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.
CD4 T-cells/million cellsGSK1437173A Vaccine Group
Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.401.9 (298.1 to 901.9)
SecondaryAnti-glycoprotein (gE) Specific Antibody (Ab) Concentrations by Each Age Category

Anti-gE Ab concentrations as determined by ELISA by each age category (60-69 years of age \[YOA\] and ≥70 YOA at the time of initial vaccination).Antibody concentrations were presented as GMCs and expressed in mIU/mL.

Time frame:
At Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Geometric mean · mIU/mL
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations by Each Age Category
mIU/mLGSK1437173A Vaccine 60-69 YOA Sub-groupGSK1437173A Vaccine ≥ 70 YOA Sub-group
Anti-gE, Month 1088566.4 (5697.1 to 12880.9)9259.6 (7741.6 to 11075.2)
Anti-gE, Month 1207401.4 (4894.2 to 11193.1)7380.2 (6048.9 to 9004.4)
SecondaryFrequencies of Antigen-specific CD4 (2+) T-cells by Each Age Category

Antigen specific CD4 (2+) T-cells as determined by means of ICS and expressed in T-cells/million cells, by each age category (60-69 YOA and ≥ 70 YOA at the time of initial vaccination).

Time frame:
At Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Median · CD4 T-cells/million cells
Frequencies of Antigen-specific CD4 (2+) T-cells by Each Age Category
CD4 T-cells/million cellsGSK1437173A Vaccine 60-69 YOA Sub-groupGSK1437173A Vaccine ≥ 70 YOA Sub-group
CD4(2+), Month 108453.8 (233.2 to 577.6)398.9 (220.9 to 811.3)
CD4(2+), Month 120359.2 (254.9 to 885.0)429.4 (298.1 to 940.1)
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs) Related to Study Participation or to a Concurrent GSK Medication/Vaccine (Including GSK1437173A Administered During the Zoster-003 [NCT00434577] Study).

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Between Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs) Related to Study Participation or to a Concurrent GSK Medication/Vaccine (Including GSK1437173A Administered During the Zoster-003 [NCT00434577] Study).
ParticipantsGSK1437173A Vaccine Group
Number of Subjects With Any Serious Adverse Events (SAEs) Related to Study Participation or to a Concurrent GSK Medication/Vaccine (Including GSK1437173A Administered During the Zoster-003 [NCT00434577] Study).0
SecondaryAnti-gE Specific Antibody (Ab) Concentrations

Anti-gE antibody concentrations were determined by ELISA in all subjects, presented as GMCs and expressed in mIU/mL.

Time frame:
At 1 month post each re-vaccination dose (i.e. Month 121 and Month 123) and at 1 year post last re-vaccination dose (i.e., Month 134).
Reported as:
Geometric mean · mIU/mL
Anti-gE Specific Antibody (Ab) Concentrations
mIU/mLGSK1437173A Vaccine Group
Anti-gE, Month 121108199.6 (87154.2 to 134326.8)
Anti-gE, Month 12390003.6 (76754.3 to 105539.9)
Anti-gE, Month 13430066.2 (25810.3 to 35023.8)
SecondaryFrequencies of Antigen-specific CD4 (2+) T-cells, Post Re-vaccination Course.

Antigen specific CD4 (2+)T cells were determined by means of ICS and expressed in T-cells/million cells.

Time frame:
At 1 month post each re-vaccination dose (i.e. Month 121 and Month 123) and at 1 year post last re-vaccination dose (i.e., Month 134).
Reported as:
Median · CD4 T-cells/million cells
Frequencies of Antigen-specific CD4 (2+) T-cells, Post Re-vaccination Course.
CD4 T-cells/million cellsGSK1437173A Vaccine Group
CD4(2+), Month 1212563.9 (1219.9 to 4127.4)
CD4(2+), Month 1231775.5 (1181.4 to 3077.8)
CD4(2+), Month 1341196.3 (680.8 to 1850.8)
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms.

Assessed solicited local symptoms included: pain, redness and swelling at injection site. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, prevented normal every day activities. Grade 3 redness/swelling = symptoms spreading beyond a surface of (\>) 100 millimeters (mm).

Time frame:
Within 7 days (Days 0-6) after each vaccination and across doses, in the current study.
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms.
ParticipantsGSK1437173A Vaccine Group
Any Pain, Dose 141
Grade 3 Pain, Dose 11
Any Redness, Dose 119
>100 mm Redness, Dose 10
Any Swelling, Dose 111
>100 mm Swelling, Dose 10
Any Pain, Dose 226
Grade 3 Pain, Dose 22
Any Redness, Dose 217
>100 mm Redness, Dose 20
Any Swelling, Dose 27
>100 mm Swelling, Dose 20
Any Pain, Across doses46
Grade 3 Pain, Across doses2
Any Redness, Across doses27
>100 mm Redness, Across doses0
Any Swelling, Across doses16
> 100 mm Swelling, Across doses0
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms.

Assessed solicited general symptoms included: fatigue, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and temperature \[higher than or equal to (≥) 37.5 degrees Celsius (°C) for axillary, oral or tympanic route\] and ≥38.0°C for rectal route. Grade 3 fatigue, gastrointestinal symptoms, headache, myalgia, shivering = symptoms that prevented normal activity. Grade 3 temperature = defined as fever higher than (\>) 39.0°C, regardless of the route used.

Time frame:
Within 7 days (Days 0-6) after each vaccination and across doses, in the current study.
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.
ParticipantsGSK1437173A Vaccine Group
Any Fatigue, Dose 125
Grade 3 Fatigue, Dose 13
Related Fatigue, Dose 125
Any Gastrointestinal symptoms, Dose 17
Grade 3 Gastrointestinal symptoms, Dose 10
Related Gastrointestinal symptoms, Dose 17
Any Headache, Dose 112
Grade 3 Headache, Dose 13
Related Headache, Dose 112
Any Myalgia, Dose 120
Grade 3 Myalgia, Dose 11
Related Myalgia, Dose 119
Any Shivering, Dose 112
Grade 3 Shivering, Dose 12
Related Shivering, Dose 112
Any Temperature, Dose 19
>39.0°C Temperature, Dose 10
Related Temperature, Dose 18
Any Fatigue, Dose 215
Grade 3 Fatigue, Dose 21
Related Fatigue, Dose 214
Any Gastrointestinal symptoms, Dose 27
Grade 3 Gastrointestinal symptoms, Dose 20
Related Gastrointestinal symptoms, Dose 25
Any Headache, Dose 212
Grade 3 Headache, Dose 21
Related Headache, Dose 212
Any Myalgia, Dose 215
Grade 3 Myalgia, Dose 22
Related Myalgia, Dose 214
Any Shivering, Dose 28
Grade 3 Shivering, Dose 22
Related Shivering, Dose 28
Any Temperature, Dose 28
>39.0°C Temperature, Dose 20
Related Temperature, Dose 27
Any Fatigue, Across doses31
Grade 3 Fatigue, Across doses3
Related Fatigue, Across doses31
Any Gastrointestinal symptoms, Across doses11
Grade 3 Gastrointestinal symptoms, Across doses0
Related Gastrointestinal symptoms, Across doses10
Any Headache, Across doses18
Grade 3 Headache, Across doses4
Related Headache, Across doses18
Any Myalgia, Across doses29
Grade 3 Myalgia, Across doses3
Related Myalgia, Across doses27
Any Shivering, Across doses16
Grade 3 Shivering, Across doses4
Related Shivering, Across doses16
Any Temperature, Across doses15
>39.0°C Temperature, Across doses0
Related Temperature, Across doses13
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) According to the Medical Dictionary for Regulatory Activities (MedDRA) Classification in All Subjects.

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within 30 days (Days 0-29) after each vaccination in the current study.
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) According to the Medical Dictionary for Regulatory Activities (MedDRA) Classification in All Subjects.
ParticipantsGSK1437173A Vaccine Group
Any AEs14
Any Grade 3 AEs1
Any Related AEs5
SecondaryNumber of Subjects With Any, Related and Fatal SAEs.

SAEs assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

Time frame:
From Dose 1 of re-vaccination (Month 120) until study end (Month 134).
Reported as:
Count of participants · Participants
Number of Subjects With Any, Related and Fatal SAEs.
ParticipantsGSK1437173A Vaccine Group
Any SAEs7
Related SAEs0
Any Fatal SAEs0
SecondaryNumber of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs).

pIMDs assessed includes AEs that were autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related pIMDs= pIMDs assessed by the investigator as related to the vaccination.

Time frame:
From Dose 1 of re-vaccination (Month 120) until study end (Month 134).
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs).
ParticipantsGSK1437173A Vaccine Group
Any pIMDs0
Related pIMDs0

Adverse events

Collected over Solicited symptoms: During the 7 day (Day 0-6) post vaccination. Unsolicited symptoms: during the 30-day (Days 0-29) post-vaccination period; SAEs: From study start (Month 108) up to study end (Month 134).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Vaccine Group0/62 (0%)7/62 (11.3%)53/62 (85.5%)
Most frequent serious events
Most frequent serious events
EventGSK1437173A Vaccine Group
Acute myocardial infarctionCardiac disorders1/62
Atrial fibrillationCardiac disorders1/62
Atrial flutterCardiac disorders1/62
Atrial tachycardiaCardiac disorders1/62
Benign prostatic hyperplasiaReproductive system and breast disorders1/62
Retroperitoneal haematomaGastrointestinal disorders1/62
Cholecystitis acuteHepatobiliary disorders1/62
Septic shockInfections and infestations1/62
Cerebrovascular accidentNervous system disorders1/62
Most frequent other events
Showing 10 of 19
Most frequent other events
EventGSK1437173A Vaccine Group
PainGeneral disorders46/62
FatigueGeneral disorders31/62
MyalgiaMusculoskeletal and connective tissue disorders29/62
ErythemaSkin and subcutaneous tissue disorders27/62
HeadacheNervous system disorders18/62
ChillsGeneral disorders16/62
SwellingGeneral disorders16/62
PyrexiaGeneral disorders15/62
Gastrointestinal disorderGastrointestinal disorders11/62
NauseaGastrointestinal disorders1/62

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A Vaccine Group
Mean72.3 ± 4.3
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A Vaccine Group
Female43
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A Vaccine Group
White-Caucasian/European Heritage70
08

Study locations

7 sites
  • GSK Investigational Site
    Hradec Kralove, 500 01, Czechia
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68161, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97070, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Berlin, 13347, Germany
  • GSK Investigational Site
    Eskilstuna, SE-631 88, Sweden
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
09

References and documents

Publications

  • Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, Bastidas A. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162. Epub 2018 Mar 21. PubMed 29461919 ↗
  • Hastie A, Catteau G, Enemuo A, Mrkvan T, Salaun B, Volpe S, Smetana J, Rombo L, Schwarz T, Pauksens K, Herve C, Bastidas A, Schuind A. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination. J Infect Dis. 2021 Dec 15;224(12):2025-2034. doi: 10.1093/infdis/jiaa300. PubMed 32502272 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Aug 2017, 16 months.

Results were first posted in Nov 2019, 2 years 2 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 16 months is close to that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2016
First posted
Apr 13, 2016
StartActual
Apr 11, 2016
Primary completionActual
Aug 28, 2017
CompletionActual
Oct 8, 2018
Results first posted
Nov 1, 2019
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02735915
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Apr 11, 2016
Primary completion
Aug 28, 2017
Completion
Oct 8, 2018
Results posted
Nov 1, 2019
Last update
Apr 12, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion